2025/09/25

Annual update has been made to our Sustainability site.

2025/09/19

Nippon Kayaku announces IBTROZI^ⓇCapsules 200mg (taletrectinib) has been approved in Japan for patients with unresectable advanced and/or recurrent ROS1-positive non-small cell lung cancer

2025/08/25

Announcement of Joint Venture Establishment and Shareholders Agreement Execution

2025/07/09

Nippon Kayaku Selected as a Constituent of all ESG Indices by GPIF

2025/06/12

Nippon Kayaku announces IBTROZI^TM approved in the U.S. for patients with advanced ROS1-positive Non-Small Cell Lung Cancer